Our characterization of dPACS null mutants has revealed Golgi structural defects, cytokinesis failures and reduced levels of Ac-Lys40 α-tubulin which may question the use of inhibitors of HDAC6 to treat PACS1-NDD. This evidence concerns the gene PACS1 and Neurodevelopmental delay.